GFAP and amyloidosis: Previous studies in intact amyloid-bearing mice have shown that inhibition of astrocytic CaN-NFAT activity also results in a reduction in the surface area of individual hippocampal astrocytes, without altering the overall number of astrocytes [46], which may be consistent with decreased expression levels of the intermediate filament protein, GFAP.